senate Bill S1306

Amended

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of certain insured individuals

download pdf

Sponsor

Bill Status


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor
view actions

actions

  • 09 / Jan / 2013
    • REFERRED TO INSURANCE
  • 08 / Jan / 2014
    • REFERRED TO INSURANCE
  • 21 / Jan / 2014
    • AMEND AND RECOMMIT TO INSURANCE
  • 21 / Jan / 2014
    • PRINT NUMBER 1306A

Summary

Requires that insurance companies provide coverage for surveillance tests for ovarian cancer of insured individuals who are deemed to be at risk for ovarian cancer.

do you support this bill?

Bill Details

See Assembly Version of this Bill:
A1916
Versions:
S1306
S1306A
Legislative Cycle:
2013-2014
Current Committee:
Senate Insurance
Law Section:
Insurance Law
Laws Affected:
Amd ยงยง3216, 3221 & 4303, Ins L
Versions Introduced in Previous Legislative Cycles:
2011-2012: S6604, A839A
2009-2010: A6475, A6475
2007-2008: A5931, A5931

Sponsor Memo

BILL NUMBER:S1306

TITLE OF BILL:
An act
to amend the insurance law, in relation to providing coverage for
surveillance tests for ovarian cancer

PURPOSE OR GENERAL IDEA OF BILL:
To require insurers to cover surveillance tests for ovarian cancer for
female insureds who are at risk for this type of cancer

SUMMARY OF SPECIFIC PROVISIONS:
Adds a new paragraph 30 to Subsection (i) of section 3216 of the
insurance law. Adds a new paragraph 19 to Subsection (k) of section
3221 of the insurance law. Adds a new subsection (jj) to Section 4303
of the insurance law.

Paragraph 30, paragraph 19 and subsection (jj) all provide that every
policy that provides medical, major medical or similar comprehensive
type coverage shall provide coverage for surveillance tests for
ovarian cancer for an insured who is at risk for ovarian cancer. An
insured is deemed to be at risk if: she has a family history of one
or more first degree relatives with ovarian cancer; three or more
female relatives with breast cancer or nonpolvposis colorectal
cancer; she tests positive for BRCA 1 or BRCA 2 mutations.
Surveillance tests for ovarian cancer shall mean annual screening for
ovarian cancer using: CA-125 serum tumor maker testing; transvaginal
ultrasound; and pelvic examination.

JUSTIFICATION:
Ovarian cancer gives no warning signs and is very difficult to detect.
Early detection through surveillance tests and treatment are the keys
to stopping this deadly disease.

PRIOR LEGISLATIVE HISTORY:
2005/06 - A.9840 - Referred to Insurance
2007/08 - A.5931 - Referred to Insurance
2009/10 - A.6475 - Held in Insurance
2011/2012 - S.6604 - Referred to Insurance

FISCAL IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS:
Minimal.

EFFECTIVE DATE:
This act shall take effect immediately and shall apply
to any policy issued, renewed, or modified after such effective date.

view bill text
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  1306

                       2013-2014 Regular Sessions

                            I N  S E N A T E

                               (PREFILED)

                             January 9, 2013
                               ___________

Introduced  by Sen. STAVISKY -- read twice and ordered printed, and when
  printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to providing coverage for
  surveillance tests for ovarian cancer

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1.  Subsection  (i)  of  section 3216 of the insurance law is
amended by adding a new paragraph 30 to read as follows:
  (30) EVERY POLICY THAT  PROVIDES  MEDICAL,  MAJOR-MEDICAL  OR  SIMILAR
COMPREHENSIVE-TYPE  COVERAGE  SHALL  PROVIDE  COVERAGE  FOR SURVEILLANCE
TESTS FOR OVARIAN CANCER FOR AN INSURED  WHO  IS  AT  RISK  FOR  OVARIAN
CANCER.  (A) FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE
AT RISK IF:
  (I) SHE HAS A FAMILY HISTORY OF:
  1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  3. NONPOLYPOSIS COLORECTAL CANCER; OR
  (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (B) FOR PURPOSES OF THIS SUBSECTION, SURVEILLANCE  TESTS  FOR  OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (I) CA-125 SERUM TUMOR MARKER TESTING;
  (II) TRANSVAGINAL ULTRASOUND; AND
  (III) PELVIC EXAMINATION.
  S 2. Subsection (k) of section 3221 of the insurance law is amended by
adding a new paragraph 19 to read as follows:
  (19) EVERY GROUP OR BLANKET POLICY DELIVERED OR ISSUED FOR DELIVERY IN
THIS  STATE  WHICH PROVIDES HOSPITAL, SURGICAL OR MEDICAL COVERAGE SHALL
INCLUDE COVERAGE FOR  SURVEILLANCE  TESTS  FOR  OVARIAN  CANCER  FOR  AN
INSURED  WHO  IS  AT  RISK  FOR OVARIAN CANCER. (A) FOR PURPOSES OF THIS
SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF:

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD04283-01-3

S. 1306                             2

  (I) SHE HAS A FAMILY HISTORY OF:
  1. ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  2. THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  3. NONPOLYPOSIS COLORECTAL CANCER; OR
  (II) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (B)  FOR  PURPOSES  OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (I) CA-125 SERUM TUMOR MARKER TESTING;
  (II) TRANSVAGINAL ULTRASOUND; AND
  (III) PELVIC EXAMINATION.
  S 3. Section 4303 of the insurance law is  amended  by  adding  a  new
subsection (jj) to read as follows:
  (JJ)  A HEALTH SERVICE CORPORATION OR MEDICAL EXPENSE INDEMNITY CORPO-
RATION   WHICH    PROVIDES    MEDICAL,    MAJOR-MEDICAL    OR    SIMILAR
COMPREHENSIVE-TYPE COVERAGE MUST PROVIDE COVERAGE FOR SURVEILLANCE TESTS
FOR OVARIAN CANCER FOR AN INSURED WHO IS AT RISK FOR OVARIAN CANCER. (1)
FOR PURPOSES OF THIS SUBSECTION, AN INSURED IS DEEMED TO BE AT RISK IF:
  (A) SHE HAS A FAMILY HISTORY OF:
  (I) ONE OR MORE FIRST-DEGREE RELATIVE WITH OVARIAN CANCER;
  (II) THREE OR MORE FEMALE RELATIVES WITH BREAST CANCER; OR
  (III) NONPOLYPOSIS COLORECTAL CANCER; OR
  (B) SHE TESTS POSITIVE FOR BRCA1 OR BRCA2 MUTATIONS.
  (2)  FOR  PURPOSES  OF THIS SUBSECTION, SURVEILLANCE TESTS FOR OVARIAN
CANCER SHALL MEAN ANNUAL SCREENING FOR OVARIAN CANCER USING:
  (A) CA-125 SERUM TUMOR MARKER TESTING;
  (B) TRANSVAGINAL ULTRASOUND; AND
  (C) PELVIC EXAMINATION.
  S 4. This act shall take effect immediately and  shall  apply  to  any
policy issued, renewed, or modified after such effective date.

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.